⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297372 | 1.00 | — | — | |
| SCHEMBL12519877 | 1.00 | — | — | |
| SCHEMBL21134724 | 0.82 | BMP1 (0.43) | — | |
| SCHEMBL21134870 | 0.82 | BMP1 (0.43) | — | |
| SCHEMBL11111414 | 0.81 | — | — | |
| SCHEMBL10786566 | 0.81 | — | — | |
| SCHEMBL1632802 | 0.80 | — | — | |
| SCHEMBL8352097 | 0.79 | PTGS1 (0.55) | — | |
| SCHEMBL21510761 | 0.79 | MMP2 (0.41) | — | |
| SCHEMBL12534363 | 0.78 | DPP7 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3508476-B1 | AMINO MERCAPTAN COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PROTECTION AGAINST RADIATION | SHANGHAI KECHOW PHARMA INC (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-9814787-B2 | Luciferin amides | UNIVERSITY OF MASSACHUSETTS (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814787-B2 | Luciferin amides | UNIVERSITY OF MASSACHUSETTS (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814787-B2 | Luciferin amides | UNIVERSITY OF MASSACHUSETTS (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160279268-A1 | Luciferin Amides | UNIVERSITY OF MASSACHUSETTS | 2016-09-29 | — | — | US | disclosed |
| US-20160279268-A1 | Luciferin Amides | UNIVERSITY OF MASSACHUSETTS | 2016-09-29 | — | — | US | disclosed |
| US-20160279268-A1 | Luciferin Amides | UNIVERSITY OF MASSACHUSETTS | 2016-09-29 | — | — | US | disclosed |
| US-9370588-B2 | Luciferin amides | UNIVERSITY OF MASSACHUSETTS (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370588-B2 | Luciferin amides | UNIVERSITY OF MASSACHUSETTS (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370588-B2 | Luciferin amides | UNIVERSITY OF MASSACHUSETTS (US) | 2016-06-21 | — | — | US | disclosed |
| US-20140193340-A1 | Luciferin Amides | UNIVERSITY OF MASSACHUSETTS (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140193340-A1 | Luciferin Amides | UNIVERSITY OF MASSACHUSETTS (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140193340-A1 | Luciferin Amides | UNIVERSITY OF MASSACHUSETTS (US) | 2014-07-10 | — | — | US | disclosed |
| US-8288351-B2 | Antagonists of the bradykinin B1 receptor | AMGEN INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8278280-B2 | Antagonists of the bradykinin B1 receptor | AMGEN INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-7605120-B2 | peptides and/or conjugated peptides may be used as therapeutics or prophylactics for the treatment of diseases mediated by B1 activation, including inflammation and chronic pain states of inflammatory and neuropathic origin, septic shock, arthritis, osteoarthritis, angina, asthma, allergic rhinitis | AMGEN INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090137452-A1 | Antagonists of the bradykinin B1 receptor | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137483-A1 | Antagonists of the bradykinin B1 receptor | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090048149-A1 | Antagonists of the bradykinin B1 receptor | AMGEN INC. | 2009-02-19 | — | — | US | disclosed |